Biomarkers and prediction of anthracyclic cardiotoxicity in breast cancer
Authors:
- Eduardo Nani SilvaESEduardo Nani Silva
- Mario Luiz RibeiroMRMario Luiz Ribeiro
- Lilian Campos CaldeiraLCLilian Campos Caldeira
- Antonio José Lagoeiro JorgeAJAntonio José Lagoeiro Jorge
- Maria Luiza Garcia RosaMRMaria Luiza Garcia Rosa
- Evandro Tinoco MesquitaEMEvandro Tinoco Mesquita
- Humberto VillacortaHVHumberto Villacorta
Open Access
- 1 January 2024
- journal article
- research article
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 70 (suppl 1) , e2024S106
Abstract
Chemotherapy with doxorubicin may lead to left ventricular dysfunction. There is a controversial recommendation that biomarkers can predict ventricular dysfunction, which is one of the most feared manifestations of anthracycline cardiotoxicity.Keywords
This publication has 12 references indexed in Scilit:
- 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)European Heart Journal, 2022
- The Role of Biomarkers in Cardio-OncologyJournal of Cardiovascular Translational Research, 2020
- The Prevalence of Stages of Heart Failure in Primary Care: A Population-Based StudyJournal of Cardiac Failure, 2016
- Cancer Therapy–Related Cardiac Dysfunction and Heart FailureCirculation: Heart Failure, 2016
- Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated With Anthracyclines, Taxanes, and TrastuzumabCirculation: Cardiovascular Imaging, 2012
- The Utility of Cardiac Biomarkers, Tissue Velocity and Strain Imaging, and Cardiac Magnetic Resonance Imaging in Predicting Early Left Ventricular Dysfunction in Patients With Human Epidermal Growth Factor Receptor II–Positive Breast Cancer Treated With Adjuvant Trastuzumab TherapyJACC, 2011
- Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I EvaluationJournal of Clinical Oncology, 2010
- The Editor's Roundtable: B-Type Natriuretic PeptideThe American Journal of Cardiology, 2008
- Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose ChemotherapyCirculation, 2004
- Plasma Natriuretic Peptide Levels and the Risk of Cardiovascular Events and DeathNew England Journal of Medicine, 2004